Nuria Cirauqui
Bioengineering (Switzerland)(CH)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Neuropeptides and Animal Physiology, Trypanosoma species research and implications, Synthesis and Biological Evaluation, Research on Leishmaniasis Studies
Most-Cited Works
- → Cryo-EM structure of aerolysin variants reveals a novel protein fold and the pore-formation process(2016)204 cited
- → LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders(2013)151 cited
- → Single-molecule sensing of peptides and nucleic acids by engineered aerolysin nanopores(2019)124 cited
- → Aerolysin nanopores decode digital information stored in tailored macromolecular analytes(2020)99 cited
- → Mapping the sensing spots of aerolysin for single oligonucleotides analysis(2018)97 cited
- → Discovery of Aminobenzyloxyarylamides as κ Opioid Receptor Selective Antagonists: Application to Preclinical Development of a κ Opioid Receptor Antagonist Receptor Occupancy Tracer(2011)82 cited
- → Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography(2011)67 cited
- → Structural, physicochemical and dynamic features conserved within the aerolysin pore-forming toxin family(2017)66 cited
- → A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models(2016)60 cited
- → Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor(2019)56 cited